Home
Storia in 1 fonti
Durvalumab Plus BCG Cut Early Recurrence of High-Risk Bladder Cancer
POTOMAC data support a year's worth of immuontherapy paired with BCG induction and maintenance
Raccontata da
medpagetoday.com
- ·
Durvalumab Plus BCG Cut Early Recurrence of High-Risk Bladder Cancer
POTOMAC data support a year's worth of immuontherapy paired with BCG induction and maintenance
- ·
Half of Patients With Post-BCG Bladder Cancer Achieve CR With Nonviral Gene Therapy
Detalimogene voraplasmid lead to numerous durable complete responses with favorable safety